Design Therapeutics is living up to its name. After seeing adverse events in its phase 1 rare disease trial, the biotech has redesigned the formulation to counter the problem—but the developments have ...

The MSCI global stock index notched its biggest first-half of a year percentage drop on record on Thursday, while the U.S. benchmark S&P 500 had its steepest percentage drop for the first six months ...